PHP
Parkman Healthcare Partners Portfolio holdings
AUM
$864M
This Quarter Return
+20.97%
1 Year Return
+33.7%
3 Year Return
+258.24%
5 Year Return
+878.92%
10 Year Return
–
AUM
$815M
AUM Growth
+$815M
(+15%)
Cap. Flow
+$60M
Cap. Flow
% of AUM
7.37%
Top 10 Holdings %
Top 10 Hldgs %
31.52%
Holding
117
New
28
Increased
37
Reduced
32
Closed
17
Top Buys
| 1 |
Eli Lilly
LLY
|
$25M |
| 2 |
Cooper Companies
COO
|
$21.3M |
| 3 |
Fortrea Holdings
FTRE
|
$17.2M |
| 4 |
Schrodinger
SDGR
|
$16.1M |
| 5 |
Oscar Health
OSCR
|
$12.4M |
Top Sells
| 1 |
Amgen
AMGN
|
$17.7M |
| 2 |
Boston Scientific
BSX
|
$15.6M |
| 3 |
Keros Therapeutics
KROS
|
$12.1M |
| 4 |
Mettler-Toledo International
MTD
|
$9.1M |
| 5 |
Humana
HUM
|
$8.28M |
Sector Composition
| 1 | Healthcare | 99.46% |
| 2 | Industrials | 0.54% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
DCPH
26
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
| $11.5M | 1.41% | 729,230 +168,205 | +30% | +$2.65M |
|
27
Day One Biopharmaceuticals
DAWN
$769M
| $11.4M | 1.4% | 691,812 +66,063 | +11% | +$1.09M |
|
28
Becton Dickinson
BDX
$55.3B
| $11.3M | 1.38% | 45,597 -21,861 | -32% | -$5.41M |
|
29
MannKind Corp
MNKD
$1.41B
| $10.9M | 1.34% | 2,405,936 -92,688 | -4% | -$420K |
|
30
Arcellx
ACLX
$3.85B
| $10.9M | 1.34% | 156,598 -11,664 | -7% | -$811K |
|
31
Vaxcyte
PCVX
$4B
| $10.2M | 1.26% | 149,956 -117,638 | -44% | -$8.04M |
|
32
Sutro Biopharma
STRO
$72.7M
| $10.1M | 1.24% | 1,790,051 +587,620 | +49% | +$3.32M |
|
33
Xenon Pharmaceuticals
XENE
$2.98B
| $9.64M | 1.18% | 223,942 -70,846 | -24% | -$3.05M |
|
34
Thermo Fisher Scientific
TMO
$186B
| $9.05M | 1.11% | 15,572 +5,572 | +56% | +$3.24M |
|
|
VRNA
35
Verona Pharma
VRNA
$9.16B
| $8.52M | 1.05% | 529,520 +24,778 | +5% | +$399K |
|
36
Castle Biosciences
CSTL
$696M
| $8.14M | 1% | 367,408 +10,252 | +3% | +$227K |
|
37
LivaNova
LIVN
$3.08B
| $8.11M | 1% | +145,000 | New | +$8.11M |
|
38
Elevance Health
ELV
$71.8B
| $7.86M | 0.96% | +15,164 | New | +$7.86M |
|
39
Haemonetics
HAE
$2.63B
| $7.76M | 0.95% | 90,962 +21,022 | +30% | +$1.79M |
|
40
Travere Therapeutics
TVTX
$1.56B
| $7.47M | 0.92% | 968,420 -50,392 | -5% | -$389K |
|
41
Ironwood Pharmaceuticals
IRWD
$214M
| $7.4M | 0.91% | 850,000 +729,348 | +605% | +$6.35M |
|
42
Disc Medicine
IRON
$2.07B
| $6.7M | 0.82% | 107,593 +14,722 | +16% | +$917K |
|
43
Ventyx Biosciences
VTYX
$171M
| $6.64M | 0.82% | +1,208,099 | New | +$6.64M |
|
|
AVDL
44
Avadel Pharmaceuticals
AVDL
$1.43B
| $6.55M | 0.8% | +387,770 | New | +$6.55M |
|
45
Teva Pharmaceuticals
TEVA
$21.1B
| $6.4M | 0.79% | +453,590 | New | +$6.4M |
|
46
Ionis Pharmaceuticals
IONS
$6.8B
| $6.13M | 0.75% | 141,499 -69,901 | -33% | -$3.03M |
|
47
CVRx
CVRX
$205M
| $6.05M | 0.74% | 332,090 +92,090 | +38% | +$1.68M |
|
|
NARI
48
DELISTED
Inari Medical, Inc. Common Stock
NARI
| $6.01M | 0.74% | +125,338 | New | +$6.01M |
|
49
Veracyte
VCYT
$2.39B
| $5.63M | 0.69% | 254,092 +16,776 | +7% | +$372K |
|
|
SLN
50
Silence Therapeutics
SLN
$227M
| $5.28M | 0.65% | 244,471 +11,529 | +5% | +$249K |
|